<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744026</url>
  </required_header>
  <id_info>
    <org_study_id>SC9-GBM-01</org_study_id>
    <nct_id>NCT03744026</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9</brief_title>
  <acronym>SC9-GBM-01</acronym>
  <official_title>A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Blood-brain Barrier (BBB) by Low Intensity Pulsed Ultrasound With the SonoCloud-9 Implantable Device in Recurrent Glioblastoma Patients Eligible for Surgery and for Carboplatin Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CarThera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CarThera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care
      for patients with GBM includes surgery, radiotherapy and chemotherapy. Despite this
      aggressive treatment, the overall median survival of patients with GBM remains at 15-20
      months.

      In more than 95% of cases, tumor recurrence is observed within 2 cm to 3 cm of the resection
      cavity within 4-7 months after initial treatments. One of the main causes of recurrence is
      the inability of chemotherapies to enter the brain from the systemic circulation due to the
      blood-brain barrier (BBB). The BBB is unique to cerebral blood vessels and blocks most drugs
      from entering the brain in sufficient concentrations.

      The SonoCloud-9 (SC9) System delivers ultrasound to locally and transiently increase the
      permeability of the BBB to allow the passage of drugs into the cerebral parenchyma. The SC9
      is dimensioned to cover the resection area and surrounding tissues in patients with recurrent
      GBM. The large sonicated volume covered by the SC9 device allows for broad BBB disruption and
      should allow for carboplatin chemotherapy to penetrate the surrounding tumor infiltrative
      area. By enhancing drug concentrations, it is hypothesized that further disease progression
      will be prevented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label, Phase 1/2a, multicenter, single-arm, interventional trial that
      will first evaluate the dose limiting toxicity (DLT) of escalating numbers of ultrasound
      beams at constant acoustic pressure using a standard escalation (Phase 1) and then confirm
      the safety and efficacy of BBB opening (Phase 2a expansion).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) of number of activated ultrasound beams</measure>
    <time_frame>15 days after the first sonication treatment</time_frame>
    <description>DLT will be evaluated using imaging (MRI) and clinical examination, as CTCAE that occurs within 2 weeks of the first sonication and that does not respond to optimal medical management (including steroids) within 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood-Brain Barrier (BBB) opening</measure>
    <time_frame>At the end of the first three sonication treatments (treatment occurs every 4 weeks)</time_frame>
    <description>BBB opening will be evaluated by contrast-enhanced T1w magnetic resonance imaging (MRI)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma, Adult</condition>
  <arm_group>
    <arm_group_label>SonoCloud-9 Ultrasound + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SonoCloud-9</intervention_name>
    <description>Escalating numbers of ultrasound beams at constant acoustic pressure</description>
    <arm_group_label>SonoCloud-9 Ultrasound + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose of carboplatin infusion is AUC4-6</description>
    <arm_group_label>SonoCloud-9 Ultrasound + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥ 18 years, able and willing to give signed and informed consent.

          2. Patient with histologically proven recurrent de novo GBM:

               1. After at least a first-line standard of care (maximal safe resection, if
                  feasible, radiation with temozolomide [TMZ], then TMZ);

               2. Any recurrence;

               3. Bevacizumab-naïve.*

          3. Patient eligible for carboplatin-based chemotherapy.

          4. Patient eligible for a surgical resection.

          5. Maximal tumor diameter at inclusion (pre surgery) ≤ 70 mm in T1wMRI.

          6. Patients should be stable, without evidence of a midline shift, significant
             peritumoral edema, or rapid progression of clinical symptoms.

          7. Karnofsky performance status ≥ 70.

          8. Patient receiving prednisone dose ≤ 40 mg (dexamethasone ≤ 6 mg) for at least 7 days.

        Key Exclusion Criteria:

          1. Multifocal tumor (unless all localized in a 70 mm diameter area).

          2. Patients at risk of surgery site infection (2 or more previous craniotomies,
             neurosurgery within the last 3 months, poor skin condition, and/or previously infected
             surgical field).

          3. Posterior fossa tumor.

          4. Uncontrolled epilepsy.

          5. Patients with evidence of uncontrolled intracranial pressure.

          6. Patients with known intracranial aneurism or having presented intra-tumor spontaneous
             hemorrhage.

          7. Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer,
             non resorbable dura substitute, or reservoirs.

          8. Patients with medical need to continue antiplatelet therapy.

          9. Patients with known or suspected active or chronic infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed IDBAIH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carole DESSEAUX</last_name>
    <phone>+33 (0)1 57 27 46 84</phone>
    <email>carole.desseaux@carthera.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger STUPP, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John DE GROOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MENEI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François DUCRAY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHINOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed IDBAIH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre CARPENTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.carthera.eu</url>
    <description>CarThera</description>
  </link>
  <reference>
    <citation>Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086.</citation>
    <PMID>27306666</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Glioblastoma</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Blood-brain barrier</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>SonoCloud</keyword>
  <keyword>Low Intensity Pulsed Ultrasound (LIPU)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

